| Followers | 3 |
| Posts | 313 |
| Boards Moderated | 0 |
| Alias Born | 06/18/2013 |
Wednesday, May 01, 2019 2:25:56 PM
Joe Dowling, CEO of CV Sciences, Inc., was featured on TDAmeritrade discussing the company’s expansion into the Food, Drug & Mass Channel & the current research that is being conducted on #hemp CBD.
Dowling discussed the recent positive research on PTSD. "I think the results were very promising" Dowling said. "Again this is just the beginning of the research."
Dowling went on to stress that PTSD is very hard to treat and that opioids are currently the front-line treatment. "If there is alternative to that, and we certainly think CBD can be an alternative, that will be very positive."
Dowling also discussed the addition of CVS as a major distributor who he now considers a partner. He explained the large retailers are starting with topical, but ingestible products are soon.
Click the link below to watch the full interview. #CVSI http://bit.ly/2Vb8D0f
Dowling discussed the recent positive research on PTSD. "I think the results were very promising" Dowling said. "Again this is just the beginning of the research."
Dowling went on to stress that PTSD is very hard to treat and that opioids are currently the front-line treatment. "If there is alternative to that, and we certainly think CBD can be an alternative, that will be very positive."
Dowling also discussed the addition of CVS as a major distributor who he now considers a partner. He explained the large retailers are starting with topical, but ingestible products are soon.
Click the link below to watch the full interview. #CVSI http://bit.ly/2Vb8D0f
Recent CVSI News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:10:09 PM
- CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results • ACCESS Newswire • 05/14/2026 08:00:00 PM
- CV Sciences, Inc. To Announce First Quarter 2026 Results On May 14, 2026 • ACCESS Newswire • 05/12/2026 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 08:04:10 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 09:14:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:06:03 PM
- CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results • ACCESS Newswire • 03/26/2026 08:00:00 PM
- CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026 • ACCESS Newswire • 03/24/2026 09:00:00 PM
- CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth • ACCESS Newswire • 03/10/2026 09:00:00 PM
- CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness • ACCESS Newswire • 02/26/2026 01:30:00 PM
- CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD • ACCESS Newswire • 12/23/2025 12:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:19:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:04:08 PM
- CV Sciences, Inc. Reports Third Quarter 2025 Financial Results • ACCESS Newswire • 11/13/2025 09:00:00 PM
- CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025 • ACCESS Newswire • 11/10/2025 11:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2025 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:24:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 09:23:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2025 08:01:09 PM
